{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:08:23Z","timestamp":1780463303804,"version":"3.54.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) is a major complication of type 2 diabetes mellitus (T2DM) and a leading cause of end-stage kidney disease (ESKD). This study aimed to investigate the association between stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index with renal outcomes in patients with Chronic Kidney Disease (CKD) initiating finerenone therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 387 adults with DKD and CKD stages 1\u20134 who initiated finerenone therapy between January 2023 and December 2025. The primary composite renal endpoint included sustained \u226540% eGFR decline or progression to ESKD. Secondary outcomes were absolute UACR change at 12\u202fmonths and annualized eGFR decline rate. Cox proportional hazards models evaluated their associations with renal outcomes, adjusted for clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary endpoint was reached by 62 patients (16.0%). Higher baseline SHR and TyG were associated with worse renal outcomes. In multivariable analysis, the highest SHR tertile (T3) had a 2.52-fold increased risk (95% CI 1.48\u20134.29;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001) and the highest TyG tertile (T3) had a 1.96-fold increased risk (95% CI 1.22\u20133.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006) compared to the lowest tertiles. Subgroup analyses showed stronger associations in advanced CKD stages. At 12\u202fmonths, high-index groups had attenuated UACR reduction and accelerated eGFR decline. Adding SHR and TyG to the clinical model improved predictive performance, with a C-statistic increase from 0.70 to 0.78.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher SHR and TyG values were independently associated with worse renal outcomes in patients with DKD initiating finerenone therapy. These biomarkers could enhance predictive models and inform targeted interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1802071","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:52:11Z","timestamp":1780462331000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stress hyperglycemia ratio (SHR) and triglyceride-glucose index (TYG) associated with renal response to finerenone in diabetic kidney disease: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Anqi","family":"Chen","sequence":"first","affiliation":[{"name":"Emergency Department, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Zou","sequence":"additional","affiliation":[{"name":"Emergency Department, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Emergency Department, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Yao","sequence":"additional","affiliation":[{"name":"Emergency Department, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Qian","sequence":"additional","affiliation":[{"name":"Emergency Department, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Shao","sequence":"additional","affiliation":[{"name":"Emergency Department, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e76498","DOI":"10.7759\/cureus.76498","article-title":"The pathophysiology and vascular complications of diabetes in chronic kidney disease: a comprehensive review","volume":"16","author":"Hauwanga","year":"2024","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","article-title":"Diabetic kidney disease: challenges, advances, and opportunities","volume":"6","author":"Chen","year":"2020","journal-title":"Kidney Dis-Basel"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10741-025-10520-3","article-title":"The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment","volume":"30","author":"Taub","year":"2025","journal-title":"Heart Fail Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4103\/ijem.ijem_376_21","article-title":"Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: a meta-analysis","volume":"26","author":"Dutta","year":"2022","journal-title":"Indian J Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15 1427727","DOI":"10.3389\/fendo.2024.1427727","article-title":"Association between different insulin resistance indices and all-cause mortality in patients with diabetic kidney disease: a prospective cohort study","volume":"15","author":"Zhu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13098-024-01324-w","article-title":"Association between stress hyperglycemia ratio and diabetes mellitus mortality in American adults: a retrospective cohort study and predictive model establishment based on machine learning algorithms (NHANES 2009\u20132018)","volume":"16","author":"Yan","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"101941","DOI":"10.1016\/j.pmedr.2022.101941","article-title":"Triglyceride glucose index: a new biomarker in predicting cardiovascular risk","volume":"29","author":"Ara\u00fajo","year":"2022","journal-title":"Prev Med Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12882-025-03984-w","article-title":"Association between triglyceride-glucose index and clinical outcomes among patients with chronic kidney disease: a meta-analysis","volume":"26","author":"Tuo","year":"2025","journal-title":"BMC Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.2147\/DMSO.S318255","article-title":"Relationship between the TyG index and diabetic kidney disease in patients with Type-2 diabetes mellitus","volume":"14","author":"Lv","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12933-023-01883-8","article-title":"High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study","volume":"22","author":"Song","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes Management in Chronic Kidney Disease","volume":"9","year":"2020","journal-title":"Kidneys Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1210\/jc.2015-2660","article-title":"Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio","volume":"100","author":"Roberts","year":"2015","journal-title":"J Clin Endocr Metab"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12933-024-02457-y","article-title":"Trajectories of triglyceride-glucose index changes and their association with all-cause and cardiovascular mortality: a competing risk analysis","volume":"23","author":"Lee","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2220\/biomedres.46.83","article-title":"Finerenone alleviates the high glucose-induced fibrosis in HK-2 cells by inhibiting EMT via the TGF-\u03b21\/Smads signaling","volume":"46","author":"Wang","year":"2025","journal-title":"Biomed Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Brit J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.nefroe.2023.09.002","article-title":"Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease","volume":"43","author":"G\u00f3rriz","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12933-025-02762-0","article-title":"Combined assessment of stress hyperglycemia ratio and glycemic variability to predict all-cause mortality in critically ill patients with atherosclerotic cardiovascular diseases across different glucose metabolic states: an observational cohort study with machine learning","volume":"24","author":"Wang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-025-02751-3","article-title":"Relationship between stress hyperglycaemic ratio (SHR) and critical illness: a systematic review","volume":"24","author":"Song","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-025-02610-1","article-title":"The association between stress-induced hyperglycemia ratio and cardiovascular events as well as all-cause mortality in patients with chronic kidney disease and diabetic nephropathy","volume":"24","author":"Cao","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e939482","DOI":"10.12659\/MSM.939482","article-title":"The triglyceride glucose (TyG) index as a sensible marker for identifying insulin resistance and predicting diabetic kidney disease","volume":"29","author":"Li","year":"2023","journal-title":"Med Sci Monit"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s11357-023-01044-5","article-title":"Baseline and usual triglyceride-glucose index and the risk of chronic kidney disease: a prospective cohort study","volume":"46","author":"Kunutsor","year":"2024","journal-title":"Geroscience"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-025-02709-5","article-title":"Joint association of the triglyceride-glucose index and stress hyperglycemia ratio with incidence and mortality risks of new-onset atrial fibrillation during sepsis: a retrospective cohort study","volume":"24","author":"Zuo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"15 1411486","DOI":"10.3389\/fendo.2024.1411486","article-title":"The threshold effect of triglyceride glucose index on diabetic kidney disease risk in patients with type 2 diabetes: unveiling a non-linear association","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-024-02228-9","article-title":"Associations between cardiometabolic indices and the risk of diabetic kidney disease in patients with type 2 diabetes","volume":"23","author":"Yan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2499228","DOI":"10.1080\/0886022X.2025.2499228","article-title":"Stress hyperglycemia ratio as a predictor of acute kidney injury and its outcomes in critically ill patients","volume":"47","author":"Lin","year":"2025","journal-title":"Ren Fail"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e17995","DOI":"10.1097\/MD.0000000000017995","article-title":"The triglyceride glucose index can predict newly diagnosed biopsy-proven diabetic nephropathy in type 2 diabetes: a nested case control study","volume":"98","author":"Shang","year":"2019","journal-title":"Medicine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/jdi.13371","article-title":"Association between the triglyceride-glucose index and diabetic nephropathy in patients with type 2 diabetes: a cross-sectional study","volume":"12","author":"Liu","year":"2020","journal-title":"J Diabetes Investig"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1802071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:52:29Z","timestamp":1780462349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1802071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":28,"alternative-id":["10.3389\/fmed.2026.1802071"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1802071","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1802071"}}